Sue Pavord
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sue Pavord has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Quentin A. Hill
Leeds Teaching Hospitals NHS Trust Leeds UK
4 shared publications - Beverley Jane Hunt
Guy's and St Thomas' NHS Foundation Trust, London, UK
3 shared publications - Michael J. R. Desborough
Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
3 shared publications - Catherine N. Bagot
Department of Haematology Glasgow Royal Infirmary Glasgow UK
2 shared publications - Cheng-Hock Toh
Department of Clinical Infection, Microbiology and Immunology University of Liverpool Liverpool UK
2 shared publications - Drew Provan
Department of Haematology, Barts and the London School of Medicine, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 842-846
Liaison haematology in the United Kingdom: Workforce perspectives of workload and labour demand
- 25 June 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (2) , 842-846
Open AccessLiaison haematology in the United Kingdom: Workforce perspectives of workload and labour demand
- 27 March 2026
- Published by SAGE Publications in Obstetric Medicine
Thrombotic microangiopathy overlap syndrome in pregnancy
In these two cases, we highlight the concept of pregnancy-associated thrombotic microangiopathy (TMA) overlap syndrome, where two different TMAs occur together, likely one driving another. Thrombotic microangiopathies occurring in pregnancy threaten the lives of both mother and fetus, and yet precise diagnosis may be difficult because of overlapping clinical and laboratory features. The three main syndromes to be considered are thrombotic thrombocytopenic purpura (TTP) – an acute disorder caused by severe ADAMTS13 deficiency; preeclampsia/HELLP syndrome – characterised by haemolysis, elevated liver enzymes, and low platelets; and atypical haemolytic uremic syndrome (aHUS)- most commonly caused by mutations in the complement regulatory genes. We present two cases where the combination of two TMAs (one most likely driving the other) led to difficult management dilemmas.
- 27 March 2026
- Published by SAGE Publications in Obstetric Medicine
Thrombotic microangiopathy overlap syndrome in pregnancy
In these two cases, we highlight the concept of pregnancy-associated thrombotic microangiopathy (TMA) overlap syndrome, where two different TMAs occur together, likely one driving another. Thrombotic microangiopathies occurring in pregnancy threaten the lives of both mother and fetus, and yet precise diagnosis may be difficult because of overlapping clinical and laboratory features. The three main syndromes to be considered are thrombotic thrombocytopenic purpura (TTP) – an acute disorder caused by severe ADAMTS13 deficiency; preeclampsia/HELLP syndrome – characterised by haemolysis, elevated liver enzymes, and low platelets; and atypical haemolytic uremic syndrome (aHUS)- most commonly caused by mutations in the complement regulatory genes. We present two cases where the combination of two TMAs (one most likely driving the other) led to difficult management dilemmas.
- Open Access
- 20 January 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 845-854
Medical haematology: Repositioning haematology at the centre of medicine
Summary: Haematology is at a crossroads, divided between haemato‐oncology and the disparate disciplines collectively known as ‘non‐malignant’ haematology. This latter term is a misnomer that devalues a spectrum of complex, life‐threatening conditions and contributes to workforce shortages and research inequities. This article argues for the formal adoption of the term Medical Haematology to redefine this domain. We chart its central role across medicine, from guiding anticoagulation, transfusion and thrombosis care across specialties to addressing global health challenges. We highlight its pioneering contributions to molecular medicine and immunotherapy, exemplified by gene therapy for haemophilia and the repurposing of chimeric antigen receptor T cells for autoimmune disease. Finally, we present a forward‐looking blueprint involving establishment of ‘Blood Teams’, revamping educational curricula and championing equity to secure the speciality's future. Embracing Medical Haematology is a strategic imperative to reflect the life‐threatening nature of many conditions within the speciality, attract trainees, rebalance research priorities and firmly re‐establish haematology's indispensable role at the heart of modern medical practice.
- 20 January 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 845-854
Open AccessMedical haematology: Repositioning haematology at the centre of medicine
Summary: Haematology is at a crossroads, divided between haemato‐oncology and the disparate disciplines collectively known as ‘non‐malignant’ haematology. This latter term is a misnomer that devalues a spectrum of complex, life‐threatening conditions and contributes to workforce shortages and research inequities. This article argues for the formal adoption of the term Medical Haematology to redefine this domain. We chart its central role across medicine, from guiding anticoagulation, transfusion and thrombosis care across specialties to addressing global health challenges. We highlight its pioneering contributions to molecular medicine and immunotherapy, exemplified by gene therapy for haemophilia and the repurposing of chimeric antigen receptor T cells for autoimmune disease. Finally, we present a forward‐looking blueprint involving establishment of ‘Blood Teams’, revamping educational curricula and championing equity to secure the speciality's future. Embracing Medical Haematology is a strategic imperative to reflect the life‐threatening nature of many conditions within the speciality, attract trainees, rebalance research priorities and firmly re‐establish haematology's indispensable role at the heart of modern medical practice.
- Open Access
Should emotional labour be a critical component in healthcare workforce modelling?
Healthcare work is emotionally intensive, yet emotional labour is overlooked in workforce modelling, with significant impact in terms of burnout and staff retention. The aim of this study was to examine emotional labour expenditure in a multi-professional group working in a large medical specialism across the UK to establish how this type of labour should be considered in workforce/labour modelling. The Discrete Emotional Labour Scale was administered to multidisciplinary members of a professional society working in haematology across the UK. Principal Component Analysis was used to understand the ways in which different emotion groups interact and contribute to emotional labour. Mann-Whitney U tests were conducted to explore differences along these principal components between cohorts separated by profession, pay grade and years of service. The findings reveal emotional labour demand can be assessed and integrated into workforce modelling. Suppressing negative and faking positive emotions significantly impact labour expenditure. Emotional labour demands vary across professional groups, pay, and years of service. Lower pay bands in clinical roles show different emotional patterns compared to higher pay bands with managerial responsibilities. Early-career professionals displayed distinct emotional labour responses compared to experienced colleagues. This highlights the need to include emotional labour demand in workforce modelling.
Open AccessShould emotional labour be a critical component in healthcare workforce modelling?
Healthcare work is emotionally intensive, yet emotional labour is overlooked in workforce modelling, with significant impact in terms of burnout and staff retention. The aim of this study was to examine emotional labour expenditure in a multi-professional group working in a large medical specialism across the UK to establish how this type of labour should be considered in workforce/labour modelling. The Discrete Emotional Labour Scale was administered to multidisciplinary members of a professional society working in haematology across the UK. Principal Component Analysis was used to understand the ways in which different emotion groups interact and contribute to emotional labour. Mann-Whitney U tests were conducted to explore differences along these principal components between cohorts separated by profession, pay grade and years of service. The findings reveal emotional labour demand can be assessed and integrated into workforce modelling. Suppressing negative and faking positive emotions significantly impact labour expenditure. Emotional labour demands vary across professional groups, pay, and years of service. Lower pay bands in clinical roles show different emotional patterns compared to higher pay bands with managerial responsibilities. Early-career professionals displayed distinct emotional labour responses compared to experienced colleagues. This highlights the need to include emotional labour demand in workforce modelling.
- Open Access
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- Vol. 12 (7) , 1-36
Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis
Background: Thrombosis with thrombocytopenia syndrome is a rare condition known to occur spontaneously or after heparin use. With the advent of COVID-19 vaccines during the pandemic, thrombosis with thrombocytopenia syndrome cases emerged post administration of adenoviral vaccines, termed vaccine-induced immune thrombosis and thrombocytopenia. In response, the thrombosis with thrombocytopenia syndrome consortium was formed to deepen our understanding of this syndrome post vaccination. Methods: The consortium employed a comprehensive approach across five work packages. This included designing cohort studies covering the entire English population and analysing local linked regional data sets to detect thrombosis with thrombocytopenia syndrome occurrences in real time. Various patient and healthy control specimens, including those from vaccinated individuals, underwent testing for antiplatelet factor 4 antibodies using three different assays. Patients who developed vaccine-induced immune thrombosis and thrombocytopenia after the AstraZeneca (AZD1222) COVID-19 vaccine underwent whole-genome and ribonucleic acid sequencing to identify genetic susceptibility factors. Multiple studies were conducted to investigate the mechanism of antiplatelet factor 4 antibody formation, including assessments of adenoviral vector structure and binding to platelet factor 4. Detailed studies were also conducted to understand the immune response to vaccines, the role of immune complexes involving platelet factor 4 and their effects on proinflammatory cytokines, neutrophil extracellular traps and platelets in the pathogenesis of the syndrome. Results: Cohort studies revealed a higher risk of arterial and venous thromboses after COVID-19 infection compared to vaccination. Specifically, regarding vaccines, the risk of thrombosis and/or thrombocytopenia was higher after the first dose of the AZD1222 vaccine but not with subsequent doses of. Regional linked data indicated that real-time ascertainment of diseases across multiple acute hospital sites’ secure data environments is not yet feasible at scale. The overall background seroprevalence of antiplatelet factor 4 antibodies was low in healthy individuals, vaccinated individuals and those infected with COVID-19. Whole-genome sequencing did not identify significant variants predisposing to vaccine-induced immune thrombosis and thrombocytopenia, with ongoing work on ribonucleic acid sequencing. An electrostatic interaction between the hexon hypervariable regions of the ChAdOx1 capsid and platelet factor 4 was suggested as a possible mechanism for antiplatelet factor 4 antibody development. Strong immune response drove the formation of neutrophil extracellular traps, significant inflammatory responses and clot formation in distant organs. Platelet activation post immune complex formation against platelet factor 4 was dependent on FcγRIIa but independent of complement, also occurring through binding with c-Mpl. T-cell reactivity against the AZD1222 vaccine indicates potential cross-reactivity with prevalent human adenoviruses. Conclusions: The consortium’s comprehensive work has uncovered new potential mechanisms of vaccine-induced immune thrombosis and thrombocytopenia and identified novel biomarkers and therapeutic strategies for further development and validation. This is crucial, as the combination of thrombosis and thrombocytopenia, alongside antiplatelet factor 4 antibodies, can occur without exposure to heparin or adenovirus vaccines. Future considerations: Recommendations include the development of a national reference laboratory and registry for diagnosis and further study of thrombosis with thrombocytopenia syndrome; future vaccine development using the adenoviral vector platform to focus on the reduction of the electrostatic interaction between viral hexons and platelet factor 4; international genomics collaboration; and studies focused on understanding the symptoms suffered by patients as well as strategies to ameliorate them. Limitations: Direct identification of vaccine-induced immune thrombosis and thrombocytopenia patients was hindered by poor recording. The rarity of vaccine-induced immune thrombosis and thrombocytopenia limited the number of patients recruited for genomic and mechanistic studies. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR135073.
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- Vol. 12 (7) , 1-36
Open AccessUnderstanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis
Background: Thrombosis with thrombocytopenia syndrome is a rare condition known to occur spontaneously or after heparin use. With the advent of COVID-19 vaccines during the pandemic, thrombosis with thrombocytopenia syndrome cases emerged post administration of adenoviral vaccines, termed vaccine-induced immune thrombosis and thrombocytopenia. In response, the thrombosis with thrombocytopenia syndrome consortium was formed to deepen our understanding of this syndrome post vaccination. Methods: The consortium employed a comprehensive approach across five work packages. This included designing cohort studies covering the entire English population and analysing local linked regional data sets to detect thrombosis with thrombocytopenia syndrome occurrences in real time. Various patient and healthy control specimens, including those from vaccinated individuals, underwent testing for antiplatelet factor 4 antibodies using three different assays. Patients who developed vaccine-induced immune thrombosis and thrombocytopenia after the AstraZeneca (AZD1222) COVID-19 vaccine underwent whole-genome and ribonucleic acid sequencing to identify genetic susceptibility factors. Multiple studies were conducted to investigate the mechanism of antiplatelet factor 4 antibody formation, including assessments of adenoviral vector structure and binding to platelet factor 4. Detailed studies were also conducted to understand the immune response to vaccines, the role of immune complexes involving platelet factor 4 and their effects on proinflammatory cytokines, neutrophil extracellular traps and platelets in the pathogenesis of the syndrome. Results: Cohort studies revealed a higher risk of arterial and venous thromboses after COVID-19 infection compared to vaccination. Specifically, regarding vaccines, the risk of thrombosis and/or thrombocytopenia was higher after the first dose of the AZD1222 vaccine but not with subsequent doses of. Regional linked data indicated that real-time ascertainment of diseases across multiple acute hospital sites’ secure data environments is not yet feasible at scale. The overall background seroprevalence of antiplatelet factor 4 antibodies was low in healthy individuals, vaccinated individuals and those infected with COVID-19. Whole-genome sequencing did not identify significant variants predisposing to vaccine-induced immune thrombosis and thrombocytopenia, with ongoing work on ribonucleic acid sequencing. An electrostatic interaction between the hexon hypervariable regions of the ChAdOx1 capsid and platelet factor 4 was suggested as a possible mechanism for antiplatelet factor 4 antibody development. Strong immune response drove the formation of neutrophil extracellular traps, significant inflammatory responses and clot formation in distant organs. Platelet activation post immune complex formation against platelet factor 4 was dependent on FcγRIIa but independent of complement, also occurring through binding with c-Mpl. T-cell reactivity against the AZD1222 vaccine indicates potential cross-reactivity with prevalent human adenoviruses. Conclusions: The consortium’s comprehensive work has uncovered new potential mechanisms of vaccine-induced immune thrombosis and thrombocytopenia and identified novel biomarkers and therapeutic strategies for further development and validation. This is crucial, as the combination of thrombosis and thrombocytopenia, alongside antiplatelet factor 4 antibodies, can occur without exposure to heparin or adenovirus vaccines. Future considerations: Recommendations include the development of a national reference laboratory and registry for diagnosis and further study of thrombosis with thrombocytopenia syndrome; future vaccine development using the adenoviral vector platform to focus on the reduction of the electrostatic interaction between viral hexons and platelet factor 4; international genomics collaboration; and studies focused on understanding the symptoms suffered by patients as well as strategies to ameliorate them. Limitations: Direct identification of vaccine-induced immune thrombosis and thrombocytopenia patients was hindered by poor recording. The rarity of vaccine-induced immune thrombosis and thrombocytopenia limited the number of patients recruited for genomic and mechanistic studies. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme as award number NIHR135073.
- Open Access
- 10 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-7
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines
Background: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) was first described after administration of adenovirus-vectored COVID-19 vaccines including Ad26.COV2.S and ChAdOx1 nCoV-19. It is not known if the clinical characteristics and outcomes of VITT after Ad26.COV2.S and ChAdOx1 nCoV-19 vaccination are different. We assessed demographic and clinical characteristics, laboratory findings and outcomes in patients with VITT after each vaccine. Methods: Spontaneous postmarketing reports of VITT after Ad26.COV2.S were identified from Janssen’s Global Safety Database and classified using NICE criteria (n = 86). Cases after ChAdOx1 nCoV-19 were identified from a published case series (n = 220). The analysis is descriptive. Results: The median age of patients with definite/probable VITT after Ad26.COV2.S or ChAdOx1 nCoV-19 vaccination is 43 and 48 years, respectively. Median time-to-onset is 11 days and 14 days post-vaccination, cerebral venous thrombosis (CVT) is present in 50.6% and 50%, and mortality is 30% and 22% of patients, respectively. Women make up 55.3% of cases after Ad26.COV2.S and 55% after ChAdOx1 nCoV-19, 74%/60% of CVT cases and 68%/62.5% of deaths. Patients present with severe thrombocytopenia, grossly elevated D-dimer, and most test positive for anti-platelet factor-4 antibodies. Patients with preexisting rare autoimmune diseases are observed despite the small sample sizes. Conclusion: Within the limitations of the data, our study finds no strong evidence for a clinically relevant difference in VITT occurring after Ad26.COV2.S or ChAdOx1 nCoV-19. Observed differences in some parameters likely result from the demographic of the populations vaccinated, and the situational and reporting differences in how, when, and where patients were identified and treated.
- 10 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-7
Open AccessComparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines
Background: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) was first described after administration of adenovirus-vectored COVID-19 vaccines including Ad26.COV2.S and ChAdOx1 nCoV-19. It is not known if the clinical characteristics and outcomes of VITT after Ad26.COV2.S and ChAdOx1 nCoV-19 vaccination are different. We assessed demographic and clinical characteristics, laboratory findings and outcomes in patients with VITT after each vaccine. Methods: Spontaneous postmarketing reports of VITT after Ad26.COV2.S were identified from Janssen’s Global Safety Database and classified using NICE criteria (n = 86). Cases after ChAdOx1 nCoV-19 were identified from a published case series (n = 220). The analysis is descriptive. Results: The median age of patients with definite/probable VITT after Ad26.COV2.S or ChAdOx1 nCoV-19 vaccination is 43 and 48 years, respectively. Median time-to-onset is 11 days and 14 days post-vaccination, cerebral venous thrombosis (CVT) is present in 50.6% and 50%, and mortality is 30% and 22% of patients, respectively. Women make up 55.3% of cases after Ad26.COV2.S and 55% after ChAdOx1 nCoV-19, 74%/60% of CVT cases and 68%/62.5% of deaths. Patients present with severe thrombocytopenia, grossly elevated D-dimer, and most test positive for anti-platelet factor-4 antibodies. Patients with preexisting rare autoimmune diseases are observed despite the small sample sizes. Conclusion: Within the limitations of the data, our study finds no strong evidence for a clinically relevant difference in VITT occurring after Ad26.COV2.S or ChAdOx1 nCoV-19. Observed differences in some parameters likely result from the demographic of the populations vaccinated, and the situational and reporting differences in how, when, and where patients were identified and treated.
- Open Access
- 9 January 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102675
Venous thromboembolism still leads on maternal death
- 9 January 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102675
Open AccessVenous thromboembolism still leads on maternal death
- Open Access
- 26 July 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (4) , 1291-1295
Anti‐platelet factor 4 immunothrombotic syndromes
Anti‐platelet factor 4 immunothrombotic syndromes comprise a group of disorders that include heparin‐induced thrombocytopenia and vaccine‐induced immune thrombocytopenia and thrombosis. These are highly prothrombotic, immunological disorders characterised by specific clinical and pathological criteria which include thrombocytopenia and thrombosis. While they are predominantly triggered by heparin and the adenoviral vector vaccines, respectively, other provoking factors have been described, as well as spontaneous forms. The unexplained co‐occurrence of thrombocytopenia with thrombosis should raise suspicion and prompt testing. This nutshell review discusses the pathophysiology, presenting features and diagnostic criteria for these conditions.
- 26 July 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (4) , 1291-1295
Open AccessAnti‐platelet factor 4 immunothrombotic syndromes
Anti‐platelet factor 4 immunothrombotic syndromes comprise a group of disorders that include heparin‐induced thrombocytopenia and vaccine‐induced immune thrombocytopenia and thrombosis. These are highly prothrombotic, immunological disorders characterised by specific clinical and pathological criteria which include thrombocytopenia and thrombosis. While they are predominantly triggered by heparin and the adenoviral vector vaccines, respectively, other provoking factors have been described, as well as spontaneous forms. The unexplained co‐occurrence of thrombocytopenia with thrombosis should raise suspicion and prompt testing. This nutshell review discusses the pathophysiology, presenting features and diagnostic criteria for these conditions.
- Open Access
- 1 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (6) , 2442-2452
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study
Summary: Few studies have reported the real‐world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associated with the use of these thrombopoietin receptor agonists (TPO‐RAs) in adult patients with ITP in the United Kingdom. Of 267 patients (median age at diagnosis, 48 years) with ITP (primary ITP [n = 218], secondary ITP [n = 49]) included in the study, 112 (42%) received eltrombopag and 155 (58%) received romiplostim as the first prescribed TPO‐RA. A platelet count ≥30 × 109/L was achieved in 89% of patients with the first TPO‐RA treatments, while 68% achieved a platelet count ≥100 × 109/L. Treatment‐free response (TFR; platelet count ≥30 × 109/L, 3 months after discontinuing treatment) was achieved by 18% of the total patients. Overall, 61 patients (23%) switched TPO‐RAs, most of whom achieved platelet counts ≥30 × 109/L with the second TPO‐RA (23/25 who switched from eltrombopag to romiplostim [92%]; 28/36 who switched from romiplostim to eltrombopag [78%]). TFR was associated with secondary ITP, early TPO‐RA initiation after diagnosis, the presence of comorbidity and no prior splenectomy or treatment with steroids or mycophenolate mofetil. Both TPO‐RAs had similar efficacy and safety profiles to those reported in clinical studies.
- 1 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (6) , 2442-2452
Open AccessReal‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study
Summary: Few studies have reported the real‐world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associated with the use of these thrombopoietin receptor agonists (TPO‐RAs) in adult patients with ITP in the United Kingdom. Of 267 patients (median age at diagnosis, 48 years) with ITP (primary ITP [n = 218], secondary ITP [n = 49]) included in the study, 112 (42%) received eltrombopag and 155 (58%) received romiplostim as the first prescribed TPO‐RA. A platelet count ≥30 × 109/L was achieved in 89% of patients with the first TPO‐RA treatments, while 68% achieved a platelet count ≥100 × 109/L. Treatment‐free response (TFR; platelet count ≥30 × 109/L, 3 months after discontinuing treatment) was achieved by 18% of the total patients. Overall, 61 patients (23%) switched TPO‐RAs, most of whom achieved platelet counts ≥30 × 109/L with the second TPO‐RA (23/25 who switched from eltrombopag to romiplostim [92%]; 28/36 who switched from romiplostim to eltrombopag [78%]). TFR was associated with secondary ITP, early TPO‐RA initiation after diagnosis, the presence of comorbidity and no prior splenectomy or treatment with steroids or mycophenolate mofetil. Both TPO‐RAs had similar efficacy and safety profiles to those reported in clinical studies.